Document is current
Any future updates will be listed below
-
Authors
Woods, Scott W.
Lympus, Cole
McGlashan, Thomas H.
Walsh, Barbara C.
Cannon, Tyrone D.
- License Information
-
More Information
Article History
Received: 15 July 2022
Accepted: 18 November 2022
First Online: 13 December 2022
Declarations
:
: An institutional review board of the Yale Human Research Protection Program (FWA00002571) determined that the research and its inclusion of an on-line participant consent as part of the training program were exempt under 45 CFR 46.104 (2)(ii) and ethics approval was therefore waived. All participants provided written informed consent to participate. All methods were carried out in accordance with relevant guidelines and regulations.
: Not applicable.
: Dr. Woods reports that during the last 36 months he has received sponsor-initiated research funding support from Boehringer-Ingelheim, Amarex, and SyneuRx. He has been a paid consultant to Boehringer-Ingelheim, New England Research Institute, and Takeda. He has been granted US patent no. 8492418 B2 for a method of treating prodromal schizophrenia with glycine agonists. Mr. Lympus and Drs. McGlashan, Walsh, and Cannon report no financial relationships with commercial interests.
